Valion Bio, Inc. — Form SCHEDULE 13D/A
Filed September 2, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 8/100
What the filing says
3i LP acquired 3,248 shares of Valion Bio common stock on September 2, 2026, at $2.9155 per share, for a total transaction value of approximately $9,475. This purchase represents a minor addition to a Schedule 13D filing and is disclosed as the sole new transaction in the past 60 days beyond those previously reported.
Why this rating
Tiny absolute dollar amount (~$9.5K) relative to $4M market cap (<0.24%); routine insider/related-party trading disclosure; no material stake or control implication.
See more from September 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.